Daxor Corporation Announces Publication in The American Journal of Surgery Concerning Blood Volume in Critically Ill Surgical Patients

NEW YORK, NY--(Marketwire - February 10, 2009) -

Daxor Corporation (AMEX: DXR), a medical instrumentation and biotechnology company, today announced the publication of the scientific article, “The availability of circulating blood volume values alters fluid management in critically ill surgical patients” in this month’s issue of The American Journal of Surgery.

In this two phase study, clinical investigators conducted a pilot study of eight (8) patients to determine if utilizing a measured blood volume from Daxor’s Blood Volume Analyzer BVA-100 would alter their fluid management in critically ill surgical patients. Upon discovering that fluid management would change 50% of the time, forty (40) additional patients were subsequently enrolled to participate in a pre- and post-interventional prospective study.

In the prospective study clinicians began treating patients based on current surrogate measures. Following their initial treatment, the blood volume analysis data was revealed to clinicians and any change in treatment due to the blood volume information was recorded. 86 blood volume measurements revealed a change in 31 cases, which represented a 36% change in treatment. No negative response occurred due to the change in treatment with a 39% improved clinical response to the treatment alteration.

The standard of care for the infusion of fluid and blood products within the critical care unit is currently not guided by a direct measurement of blood volume; rather clinicians rely on surrogate tests along with signs and symptoms, which have been shown to be relatively inaccurate. Previous studies utilizing Daxor’s BVA-100 in the critical care arena have been retrospective observational studies. This study represents the first prospective study which demonstrated that a measured blood volume contributes to improving fluid management in the critically ill surgical patient. Other studies which demonstrate specific clinical outcomes of a measured blood volume in the critical care arena are ongoing, the results of which are expected to be reported soon. The result of this study and other studies which demonstrate improvements in care are important to the adoption of the Blood Volume Analyzer becoming a standard of care.

This article can be found in the February 2009 issue, Volume 197, Number 2, pages 232-237 of the American Journal of Surgery (AJS). AJS is a peer-reviewed journal designed for the general surgeon who performs abdominal, cancer, vascular, head and neck, breast, colorectal, and other forms of surgery.

Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor’s single use diagnostic kit. For more information regarding Daxor Corporation’s Blood Volume Analyzer BVA-100, visit Daxor’s website www.Daxor.com.